Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Co.'s primary product candidate, TP-03, is an investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Co. is developing product candidates to address targeted diseases with unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. We show 12 historical shares outstanding datapoints in our TARS shares outstanding history coverage, used to compute TARS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TARS market cap history over the course of time is important for investors
interested in comparing TARS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TARS versus a peer is one thing; comparing
TARS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TARS can fluctuate over the course of history.
With this page we aim to empower investors researching TARS by allowing them to research the TARS market cap history. |
Free TARS Email Alerts:
Video: The Importance of Market Cap
